Novartis’s Beovu Launch Clouded By Safety Worries
Beovu Uncertainty Should Benefit Regeneron’s Eylea
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
You may also be interested in...
Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.
Slated to begin a Phase III later this year of ADVM-022 in wet AMD, Adverum had to scuttle a Phase II study of the gene therapy in DME after a patient suffered ocular hypotension, panuveitis and vision loss in the treated eye.
Despite the impact from COVID-19, Novartis performed strongly in the second quarter "demonstrating resilience and agility of our associates and operations," according to CEO Vas Narasimhan. However, there is cause for concern at its ophthalmogy business and those problems are certainly not all down to coronavirus.